Review Article

The Intersection of Artificial Intelligence and Big Data in Drug Discovery: A Review of Current Trends and Future Implications

Bankole Ibrahim Ashiwaju[1,2], Ochuko Felix Orikpete[3,4], Chinedum Gloria Uzougbo[5]

[1]Department of Pharmaceutical Chemistry, University of Lagos, [2]Department of R&D, Emzor Pharmaceuticals, Lagos, [3]Bristow Helicopters Nigeria Limited, ExxonMobil Qua Iboe Terminal, Eket, Akwa Ibom State, [4]Centre for Occupational Health, Safety and Environment (COHSE), Faculty of Engineering, University of Port Harcourt, Choba, Rivers State, [5]Delta State Ministry of Health, Asaba, Nigeria

Abstract

The pharmaceutical landscape has been continually evolving, adapting to the myriad technological advancements of the 21st century. Among these innovations, artificial intelligence (AI) and big data have emerged as transformative tools, altering the trajectory of drug discovery processes. This review elucidates the symbiotic relationship between AI and big data in modern drug discovery, highlighting the profound enhancements in efficiency, precision, and innovation. Drawing from current research trends, we delve into the potent capabilities of AI-powered algorithms to process, analyze, and glean insights from massive, multifaceted datasets. Furthermore, we explore the tangible impacts on drug repurposing, predictive modeling, molecular simulation, and clinical trials. Yet, this merger is not devoid of challenges. The review also critically examines inherent obstacles such as data integrity, the interpretability of AI models, and the evolving regulatory frameworks. As we gaze into the future of drug discovery, this intersection of AI and big data offers promising horizons, with implications not only for faster, more precise drug development but also for personalized, efficient patient care. This article aims to provide a comprehensive perspective on the current landscape while forecasting the transformative potential in the upcoming decades.

Keywords: Artificial intelligence, big data, drug discovery, personalized medicine, predictive modeling

Introduction

In the panorama of medical and pharmaceutical advancements, the narrative of drug discovery stands as a testament to both human innovation and the intricacies of biology.[1] Characterized by the allure of therapeutic breakthroughs on the one hand and the labyrinth of research and development (R and D) challenges on the other, drug discovery is arguably one of the most captivating yet complex facets of science.[2,3] Historically rooted in empirical methods and observatory sciences, the trajectory of drug discovery has been shaped by eons of knowledge, from ancient herbal remedies to cutting-edge, targeted therapies.[4,5] Yet, every epoch of this journey, no matter how advanced, has been beset with challenges. The age-old quest for better, faster, and more efficient ways to discover and develop novel therapeutics has remained relentless.

The dawn of the 21st century, however, introduced a paradigm shift in this quest. As we tread deeper into the age of information, two formidable entities have emerged at the forefront of numerous industries, including health care and pharmaceuticals: artificial intelligence (AI) and big data.[6] While these terms have permeated virtually every domain, their implications in drug discovery are profound, promising a revolution in the ways drugs are researched, developed, and brought to market.[7]

The scope of big data in the context of pharmaceuticals is truly expansive, comprising vast repositories of information. From genomic sequences and molecular pathways to clinical trial outcomes and patient records, data in drug discovery and development is multifaceted. The exponential growth in such data volumes over recent years is, in itself, a testament

Address for correspondence: Mr. Bankole Ibrahim Ashiwaju, Department of Pharmaceutical Chemistry, University of Lagos, Lagos, Nigeria
E-mail: ashiwajujr@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Ashiwaju BI, Orikpete OF, Uzougbo CG. The intersection of artificial intelligence and big data in drug discovery: A review of current trends and future implications. Matrix Sci Pharma 2023;7:36-42.

Received: 18-08-2023, **Revised:** 20-08-2023,
Accepted: 21-08-2023, **Published:** 24-10-2023

Access this article online

Quick Response Code:

Website: https://journals.lww.com/mtsp

DOI: 10.4103/mtsp.mtsp_14_23

to the evolution of biomedical research methodologies and technologies.[8,9] Concurrently, the realm of AI, with its roots in computational algorithms that learn, adapt, and predict, offers the tools and techniques to navigate, decipher, and harness the power of this data deluge.[10]

The convergence of AI and big data promises a transformative overhaul of the drug discovery process. With the potential to expedite drug pipelines, predict therapeutic outcomes with greater accuracy, and optimize R and D costs, this synergy could very well be the panacea for many challenges that have conventionally plagued the field. Yet, like all scientific endeavors, the integration of AI and big data into drug discovery brings its own set of challenges, ethical quandaries, and considerations.[11,12]

This review, in its essence, is an exploration of this dynamic intersection of AI, big data, and drug discovery. Through the following sections, we embark on a comprehensive journey, tracing the evolution of drug discovery, delving deep into the intricacies of big data and AI, and examining their combined impact on modern pharmaceutical research. By bridging historical insights with contemporary advancements, we aim to provide a holistic overview of current trends, challenges, and the promising horizon that beckons.

As we set forth, it's crucial to recognize that this narrative is not just a tale of technological prowess but is equally a testament to the perennial human endeavor to better understand our biology and enhance the quality of life. The interplay of AI and big data in drug discovery is, at its core, a fusion of computation with biology, of algorithms with intuition, and of data with discovery. It's a chapter in the ever-evolving story of humanity's pursuit of health, well-being, and medical breakthroughs.

The Emergence and Evolution of Artificial Intelligence in Drug Discovery

The synthesis of AI with the multifaceted realm of drug discovery represents a pioneering confluence of technology and biology. This alliance has, over time, evolved from rudimentary applications to intricate and deeply intertwined processes that are reshaping the pharmaceutical landscape.[13] In understanding this transformative journey, one must trace both the growth trajectory of AI as a technology and its symbiotic application within the drug discovery paradigm.

The inception of AI in the mid-20th century marked the dawning of an era of computational intelligence, inspired by the very neural frameworks of the human brain. The grand vision was machines that could think, learn, and evolve, paralleling human cognitive functions.[14,15] As AI technologies matured, their applicability permeated numerous sectors, with the pharmaceutical industry standing as a particularly promising frontier. The unique challenges in drug discovery–a domain characterized by vast data, intricate molecular interactions, and the high stakes of human health–posed a scenario ripe for AI's capabilities.[16]

Early interactions of AI with pharmaceuticals were primarily data-driven. The industry has long been a reservoir of colossal datasets, from molecular structures and genetic sequences to clinical trial results and patient records. Traditional data analysis methods, though meticulous, often faltered under the sheer volume and complexity of this data. AI, particularly machine learning, emerged as a solution, enabling the decoding of complex patterns, predictions of molecular interactions, and insightful extrapolations that were previously unattainable.[17-19]

This data-driven approach soon evolved into more refined applications. Drug design, for instance, underwent a paradigm shift. Instead of the traditional "brute force" methodologies that screened vast libraries of compounds, AI-driven predictive modeling emerged. Such models could forecast molecular interactions with biological targets, dramatically reducing the time and resources required in early drug discovery phases.[20] The arena of drug repurposing, too, was revolutionized. Algorithms, trained on vast pharmaceutical data repositories, could identify new therapeutic potentials for existing drugs, turning what was once a serendipitous discovery process into a systematic, data-driven endeavor.[21-23]

The scope of AI's influence was not confined to the molecular or data analysis realms. Clinical trials, historically known for their resource-intensive nature, began to see the transformative impact of AI-driven tools.[24,25] Patient recruitment, a phase often plagued by inefficiencies, became more streamlined with predictive algorithms.[26,27] Real-time data monitoring during trials ensured quicker response times, better patient safety, and improved outcomes. In the post-market phase, AI-assisted pharmacovigilance tools could rapidly detect patterns suggesting adverse drug effects, enhancing overall patient safety.[28-30]

However, this journey, while marked by significant milestones, was not devoid of challenges. The integration of AI into such a sensitive domain brought forth ethical dilemmas, especially concerning data privacy. The intricate nature of certain AI models, especially deep learning, posed transparency, and interpretability issues – a concern in an industry where understanding mechanisms of action is crucial. Moreover, the efficacy of AI models is deeply rooted in the quality of training data. Incomplete, biased, or skewed datasets could inadvertently lead to erroneous conclusions, underscoring the importance of data integrity.[31]

In retrospect, the narrative of AI's foray into drug discovery is one of evolution, collaboration, challenges, and immense potential. The convergence has accelerated research, bridged knowledge gaps, and ushered in a new era of pharmaceutical innovation. Looking forward, as AI continues its growth trajectory and the drug discovery domain grapples with ever-evolving challenges, this symbiotic relationship is poised to redefine the future of therapeutic research and development.

The Integration of Big Data in the Artificial Intelligence-driven Drug Discovery Landscape

The advent of big data in the world of drug discovery has been nothing short of revolutionary. In a domain where minutiae matter and the difference between success and failure often lies in granular details, the ability to harness vast quantities of information has fundamentally transformed the processes, outcomes, and potentials of drug development.[32,33]

Historically, drug discovery was a meticulous endeavor. Traditional methods involved the laborious testing of numerous compounds, with hopes of finding one that exhibited desired therapeutic effects.[34] This method, often likened to searching for a needle in a haystack,[35] was inherently resource-intensive and fraught with uncertainties. The vastness of the drug discovery landscape, with its innumerable molecular interactions, cellular pathways, and biological responses, demanded more efficient and insightful approaches.[36,37]

Enter big data. This term, while now ubiquitous across industries, found a particularly resonant chord in the pharmaceutical sector. For drug researchers, big data encompassed vast repositories of molecular structures, patient records, genetic information, clinical trial outcomes, and more. Each dataset, in isolation, represented a fragment of the larger therapeutic puzzle. However, the true potential lies in integrating these data points, synthesizing them into actionable insights, and harnessing this knowledge to drive informed decision-making.[38,39]

The confluence of big data with AI was a natural progression. AI algorithms, especially machine learning models, thrive on data. The more information they are fed, the better they perform in terms of accuracy, predictive power, and adaptability. In the context of drug discovery, AI became the conduit through which big data could be interpreted, analyzed, and applied.[40,41]

One of the most transformative applications has been in the realm of predictive modeling. With access to expansive datasets detailing the interactions between drugs and biological systems, AI models could preemptively forecast which compounds were likely to have therapeutic efficacy. This predictive capability reduced the need for exhaustive empirical testing, optimizing resource allocation and dramatically shortening drug development timelines.[42,43]

Furthermore, big data provided a platform for holistic patient analysis. As personalized medicine gains prominence, understanding individual genetic makeup and its implications on drug response becomes paramount. AI-driven analysis of large-scale genomic data facilitated this, enabling the tailoring of drugs to specific patient profiles, thus maximizing efficacy and minimizing adverse reactions.[44,45]

The vast datasets also aided in drug repurposing. Existing drugs, previously approved for certain conditions, could be reassessed for new therapeutic potentials. AI models, trained on extensive pharmacological data, could identify potential new applications for these drugs, offering new therapeutic avenues without the need for ground-up drug development.[46-50]

While the integration of big data and AI has undeniably accelerated the pace of drug discovery, it has not been without challenges. Ensuring data integrity is paramount. Erroneous, incomplete, or biased data can skew AI analyses, leading to misleading conclusions. In addition, the sheer volume of data presents storage and processing challenges, necessitating robust IT infrastructures. Ethical concerns, especially regarding patient data privacy and consent, have also been at the forefront of discussions.[51,52]

In essence, the seamless integration of big data into the AI-driven drug discovery landscape represents a symbiotic alliance, with each augmenting the capabilities of the other. As datasets continue to expand and AI models evolve in sophistication, this alliance promises to continually reshape the boundaries of what is possible in drug research, offering hope for more efficient, effective, and tailored therapeutic solutions in the future.

Ethical and Regulatory Challenges in Artificial Intelligence-driven Drug Discovery

The alignment of AI and big data in drug discovery has undeniably ushered in a new era of innovation, efficiency, and potential. While the positives are manifold, it is paramount to address the associated ethical and regulatory challenges that come with this intersection. Their significance cannot be understated, especially when the stakes involve human health, data privacy, and the sanctity of scientific research.[53,54]

Data privacy emerges as a paramount concern. The efficacy of AI in drug discovery hinges on its access to vast amounts of data, often encompassing sensitive patient information.[55] Every piece of data that AI systems analyze, from genetic profiles to patient histories, must be treated with the utmost respect and caution. It is crucial to ensure that data is acquired with informed consent, and its usage is transparently communicated to patients.[56,57] Beyond consent, there is the issue of data security. With rising cyber threats, pharmaceutical companies, research labs, and all stakeholders must prioritize the safeguarding of data against potential breaches.[58,59]

Moreover, there is the question of bias. The quality of AI predictions and analysis is directly proportional to the quality and diversity of the data it is trained on. Biased datasets, which might over-represent certain demographics and underrepresent others, can lead AI systems to develop drugs that cater to a segment of the population while inadvertently neglecting others. Such biases could lead to skewed drug efficacy results, potentially side-lining vulnerable or minority groups.[60,61] It's a challenge that calls for conscious data sourcing, meticulous algorithm training, and ongoing audits to ensure that AI tools serve the entirety of humanity rather than a select few.

Another pertinent issue is the 'black box' nature of many AI models. The opacity of certain complex AI algorithms makes it challenging to discern the exact decision-making pathways. In drug discovery, where understanding mechanisms and causality is vital, relying on models whose workings are not fully transparent poses a significant challenge.[62-64] Researchers and health-care professionals need to trust the tools they employ, and this trust is contingent on comprehensibility.

Regulatory challenges further compound these ethical dilemmas. The current regulatory frameworks in many regions are primarily oriented toward traditional drug discovery methods. Introducing AI-driven methodologies into the mix demands a re-evaluation of these norms. Regulatory bodies are tasked with the complex endeavor of balancing innovation with safety. They must evolve their guidelines to ensure that AI-driven drug discoveries are held to the highest standards of efficacy, safety, and ethical soundness. This might involve establishing new criteria for AI model validation, data integrity checks, and transparency mandates.[65]

The role of intellectual property in this space is also evolving. As AI systems contribute significantly to drug formulations, mechanisms, and testing, questions about patent rights and intellectual ownership arise. How do we attribute discoveries in an environment where machine intelligence plays a pivotal role? This necessitates a fresh look at intellectual property laws, ensuring they remain relevant in an AI-augmented landscape.[66]

Collaborative research, a promising avenue in AI-driven drug discovery, brings its own set of challenges. As researchers across the globe pool data, insights, and resources, issues of data sovereignty come to the fore. Different countries have varying data protection laws, and navigating this intricate web becomes essential for global collaboration to thrive.[67]

In essence, while the convergence of AI and big data in drug discovery promises a future of accelerated research, personalized medicine, and ground-breaking therapeutics, it is a journey fraught with complexities. Ethical and regulatory considerations stand as crucial pillars, ensuring that the path to innovation remains grounded in principles of fairness, transparency, and the broader welfare of humanity. Embracing these challenges and addressing them head-on is not just a responsibility; it is an imperative for all stakeholders in this transformative journey.

Future Prospects and Implications of Artificial Intelligence and Big Data in Drug Discovery

The fusion of AI and big data in drug discovery is more than just a current technological trend; it is a harbinger of a future brimming with potential and transformative possibilities. As we stand at this intersection, it is essential to look forward and contemplate what the coming years might hold, considering both the anticipated advancements and the broader implications for the pharmaceutical industry, health care, and society at large.

The first and most immediate prospect is the acceleration of drug discovery timelines.[68] Traditional drug discovery processes, marked by trial and error, and lengthy testing phases, can span over a decade from initial concept to market. With the predictive analytics capabilities of AI, powered by the vast reservoirs of big data, this timeline is poised to shrink significantly. Early-phase drug candidates can be identified with greater precision, reducing the number of failed trials and ensuring that only the most promising compounds proceed to advanced testing stages.

Beyond acceleration, there is an emerging emphasis on personalization. As AI systems become more sophisticated and the pool of available data broadens, the potential for personalized medicine becomes increasingly tangible. Instead of a one-size-fits-all approach, treatments can be tailored to individual patients based on their genetic makeup, medical history, and even lifestyle factors.[69,70] This degree of customization could dramatically improve drug efficacy, minimize adverse reactions, and optimize therapeutic outcomes.[71,72]

The democratization of drug discovery is another profound implication.[73] As AI models become more accessible and user-friendly, the barrier to entry for drug research might lower. Smaller labs, academic institutions, or even startups without the extensive resources of big pharma could leverage AI tools to undertake meaningful research, fostering a more diverse and inclusive research landscape.

Environmental sustainability, often overshadowed in discussions about drug discovery, stands to benefit from AI and big data convergence. By refining drug synthesis processes and minimizing the need for resource-intensive physical trials, the environmental footprint of drug research and production can be substantially reduced.[74-76] AI models can suggest environmentally friendly synthesis routes, optimize resource allocation, and predict potential environmental hazards of new compounds.

However, with these prospects come implications that need thoughtful consideration. As AI becomes a mainstay in drug discovery, there is the potential risk of over-reliance. While AI offers powerful tools for prediction and analysis, human expertise, intuition, and ethical judgment remain irreplaceable.[77] The pharmaceutical industry must strike a balance, ensuring that AI complements human expertise rather than seeking to replace it entirely.

The global nature of AI and big data also raises questions about equitable access. While AI-powered drug discovery holds promise for tackling rare and neglected diseases, it is crucial to ensure that the resulting therapeutics are accessible to all, irrespective of geography or socio-economic status. The industry, in collaboration with policymakers, needs to formulate strategies that prevent the emergence of a two-tiered

health-care system where AI-driven treatments are a privilege for the few.[78]

In tandem with the technical evolution, there is an impending need for educational shifts. Current and future generations of researchers, clinicians, and pharmacologists need training not just in their core disciplines but also in AI, data analytics, and computational biology. Integrating these fields into academic curricula will be pivotal in ensuring that the workforce is equipped to harness the full potential of AI-driven drug discovery.[79]

To encapsulate the key points discussed, as we gaze into the horizon, the confluence of AI and big data in drug discovery presents a landscape rich with opportunities and challenges. The potential benefits – accelerated research, personalized treatments, and democratized discovery – are immense. However, they come paired with implications that demand foresight, ethics, and collaboration across sectors. The journey ahead is intricate but holds the promise of redefining health care and ushering in an era of medicine that is more effective, inclusive, and attuned to individual needs.

Conclusion

The relentless march of technological progress has forever changed the contours of many industries, and the domain of drug discovery has proven to be no exception. At the crux of this evolution lies the confluence of AI and big data, two formidable forces that promise to redefine pharmaceutical research's future trajectory.

As we have traversed the multi-faceted landscape of this merger, it becomes evident that its implications are vast and varied. AI, with its capacity for advanced predictive modeling and rapid data processing, melds seamlessly with the massive datasets inherent to the drug discovery process. This union has paved the way for accelerated timelines in drug development, from the preliminary stages of molecule identification to the crucial phases of clinical trials. The synergistic relationship between AI and big data has not only streamlined existing processes but has also birthed novel methodologies that could have been scarcely imagined a few decades ago.

However, while the potential benefits of this integration are prodigious, it is paramount to approach this brave new world with both optimism and caution. The challenges – be they technical, regulatory, or ethical – are not insubstantial. Ensuring data quality and integrity, navigating the "black-box" nature of certain AI models, and preserving patient trust through robust data protection measures are all imperatives that the industry must grapple with. Moreover, the democratization of drug research, enabled by AI's accessibility, calls for rigorous quality control mechanisms to ensure that the science remains both innovative and impeccable.

It is also worth noting that while AI and big data offer tools of unparalleled power, the human element remains irreplaceable. The creativity, intuition, and ethical discernment of researchers, clinicians, and other stakeholders cannot be wholly replicated by algorithms. Hence, the future likely does not reside in AI replacing human expertise but rather augmenting it, amplifying our innate capacities and compensating for our limitations.

In closing, the intersection of AI and big data in drug discovery stands as a testament to humanity's ceaseless quest for knowledge and betterment. With every molecule analyzed, every model refined, and every drug developed, we edge closer to a future where diseases are better understood, treatments more personalized, and the hope for healthier lives more tangible. As the next chapters of this narrative unfold, they promise a tale of challenges met, boundaries pushed, and the inexorable progress of science and technology in the service of humankind.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y) 2017;3:651-7.
2. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest 2006;116:2837-42.
3. Frearson J, Wyatt P. Drug discovery in academia- the third way? Expert Opin Drug Discov 2010;5:909-19.
4. Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites 2012;2:303-36.
5. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules 2016;21:559.
6. Yang YC, Islam SU, Noor A, Khan S, Afsar W, Nazir S. Influential usage of big data and artificial intelligence in healthcare. Comput Math Methods Med 2021;2021:5812499.
7. Narayanan RR, Durga N, Nagalakshmi S. Impact of artificial intelligence (AI) on drug discovery and product development. Indian J Pharm Educ Res 2022;3:s387-97.
8. Glicksberg BS, Li L, Chen R, Dudley J, Chen B. Leveraging big data to transform drug discovery. Methods Mol Biol 2019;1939:91-118.
9. Kim RS, Goossens N, Hoshida Y. Use of big data in drug development for precision medicine. Expert Rev Precis Med Drug Dev 2016;1:245-53.
10. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021;26:80-93.
11. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, *et al.* The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals (Basel) 2023;16:891.
12. Liu B, He H, Luo H, Zhang T, Jiang J. Artificial intelligence and big data facilitated targeted drug discovery. Stroke Vasc Neurol 2019;4:206-13.
13. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics 2023;15:1916.
14. Erb B. Artificial Intelligence and Theory of Mind. Ulm University; 2016. p. 1-11.
15. Korteling JE, van de Boer-Visschedijk GC, Blankendaal RA, Boonekamp RC, Eikelboom AR. Human- versus artificial intelligence. Front Artif Intell 2021;4:622364.
16. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial intelligence in pharmaceutical and healthcare research. Big Data Cogn Comput 2023;7:10.
17. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: A review. AAPS J 2022;24:19.

18. Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, *et al*. Artificial intelligence in pharmaceutical sciences. Engineering 2023. [doi: 10.1016/j.eng.2023.01.014].
19. Sharma A, Virmani T, Pathak V, Sharma A, Pathak K, Kumar G, *et al.* Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine. Biomed Res Int 2022;2022:7205241.
20. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev 2019;119:10520-94.
21. Low ZY, Farouk IA, Lal SK. Drug repositioning: New approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses 2020;12:1058.
22. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: A brief overview. J Pharm Pharmacol 2020;72:1145-51.
23. Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: A systematic review on root causes, barriers and facilitators. BMC Health Serv Res 2022;22:970.
24. Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial intelligence applied to clinical trials: Opportunities and challenges. Health Technol (Berl) 2023;13:203-13.
25. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, *et al.* AI in drug discovery and its clinical relevance. Heliyon 2023;9:e17575.
26. Cai T, Cai F, Dahal KP, Cremone G, Lam E, Golnik C, *et al.* Improving the efficiency of clinical trial recruitment using an ensemble machine learning to assist with eligibility screening. ACR Open Rheumatol 2021;3:593-600.
27. Spies R, Siegfried N, Myers B, Grobbelaar SS. Concept and development of an interactive tool for trial recruitment planning and management. Trials 2021;22:189.
28. Lu Z. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf 2009;1:35-45.
29. Trifirò G, Crisafulli S. A new era of pharmacovigilance: Future challenges and opportunities. Front Drug Saf Regul 2022;2:1.
30. Ventola CL. Big data and pharmacovigilance: Data mining for adverse drug events and interactions. *P* T 2018;43:340-51.
31. Ozmen Garibay O, Winslow B, Andolina S, Antona M, Bodenschatz A, Coursaris C, *et al.* Six human-centered artificial intelligence grand challenges. Int J Hum Comput Interact 2023;39:391-437.
32. Buvailo A. New Player in Drug Discovery Promises to "Democratize" AI Solutions, Brings Flexibility. Biopharma Insight; 2022. Available from: https://www.biopharmatrend.com/post/466-receptorai-contributes-to-the-future-of-ai-based-drug-discovery-by-diversifying-its-user-base/. [Last accessed on 2023 Sep 15].
33. Tripathi MK, Nath A, Singh TP, Ethayathulla AS, Kaur P. Evolving scenario of big data and artificial intelligence (AI) in drug discovery. Mol Divers 2021;25:1439-60.
34. Katiyar C, Gupta A, Kanjilal S, Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu 2012;33:10-9.
35. Denny-Gouldson P. Needle in a Haystack! What Tech Advances are Shaping Drug Development? European Pharmaceutical Manufacturer. Publisher; 2018. Available from: https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/needle-in-a-haystack-tech-advances-in-drug-development/. [Last accessed on 2023 Sep 15].
36. Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep 2004;5:837-42.
37. Zhou SF, Zhong WZ. Drug design and discovery: Principles and applications. Molecules 2017;22:279.
38. Mallappallil M, Sabu J, Gruessner A, Salifu M. A review of big data and medical research. SAGE Open Med 2020;8:2050312120934839.
39. Tormay P. Big data in pharmaceutical R and D: Creating a sustainable R and D engine. Pharmaceut Med 2015;29:87-92.
40. Lee JW, Maria-Solano MA, Vu TN, Yoon S, Choi S. Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD). Biochem Soc Trans 2022;50:241-52.
41. Zhu H. Big data and artificial intelligence modeling for drug discovery. Annu Rev Pharmacol Toxicol 2020;60:573-89.
42. Kwofie SK, Adams J, Broni E, Enninful KS, Agoni C, Soliman ME, *et al.* Artificial Intelligence, machine learning, and big data for Ebola virus drug discovery. Pharmaceuticals (Basel) 2023;16:332.
43. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, *et al.* Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 2019;18:463-77.
44. Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, *et al.* Innovations in genomics and big data analytics for personalized medicine and health care: A review. Int J Mol Sci 2022;23:4645.
45. Hulsen T, Jamuar SS, Moody AR, Karnes JH, Varga O, Hedensted S, *et al.* From big data to precision medicine. Front Med (Lausanne) 2019;6:34.
46. Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, *et al.* Drug repurposing in malignant pleural mesothelioma: A breath of fresh air? Eur Respir Rev 2018;27:170098.
47. Lee HM, Kim Y. Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders. Schizophr Res Treatment 2016;2016:6378137.
48. Masuda T, Mimori K. Artificial intelligence-assisted drug repurposing via "chemical-induced gene expression ranking". Patterns (N Y) 2022;3:100470.
49. Mohanty S, Harun Ai Rashid M, Mridul M, Mohanty C, Swayamsiddha S. Application of artificial intelligence in COVID-19 drug repurposing. Diabetes Metab Syndr 2020;14:1027-31.
50. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, *et al*. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med Res Rev 2021;41:1427-73.
51. Li LX, Chen MS, Zhang ZY, Paulsen BS, Rise F, Huang C, *et al.* Structural features and antioxidant activities of polysaccharides from different parts of *Codonopsis pilosula* var. Modesta (Nannf.) L. T. Shen. Front Pharmacol 2022;13:937581.
52. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, *et al.* Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface 2018;15:20170387.
53. Bouhouita-Guermech S, Gogognon P, Bélisle-Pipon JC. Specific challenges posed by artificial intelligence in research ethics. Front Artif Intell 2023;6:1149082.
54. Solanki P, Grundy J, Hussain W. Operationalising ethics in artificial intelligence for healthcare: A framework for AI developers. AI Ethics 2023;3:223-40.
55. Filkins BL, Kim JY, Roberts B, Armstrong W, Miller MA, Hultner ML, *et al.* Privacy and security in the era of digital health: What should translational researchers know and do about it? Am J Transl Res 2016;8:1560-80.
56. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford) 2020;2020:baaa010.
57. Kiseleva A, Kotzinos D, De Hert P. Transparency of AI in healthcare as a multilayered system of accountabilities: Between legal requirements and technical limitations. Front Artif Intell 2022;5:879603.
58. Jalali MS, Kaiser JP. Cybersecurity in hospitals: A systematic, organizational perspective. J Med Internet Res 2018;20:e10059.
59. Javaid M, Haleem A, Singh RP, Suman R. Towards insighting cybersecurity for healthcare domains: A comprehensive review of recent practices and trends. Cyber Secur Appl 2023;1:100016. [doi: 10.1016/j.csa. 2023.100016].
60. Nazer LH, Zatarah R, Waldrip S, Ke JX, Moukheiber M, Khanna AK, *et al.* Bias in artificial intelligence algorithms and recommendations for mitigation. PLOS Digit Health 2023;2:e0000278.
61. Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: A call for open science. Patterns (N Y) 2021;2:100347.
62. Ali S, Abuhmed T, El-Sappagh S, Muhammad K, Alonso-Moral JM, Confalonieri R, *et al*. Explainable artificial intelligence (XAI): What we know and what is left to attain trustworthy artificial intelligence. Inf Fusion 2023;99:101805.
63. Khan B, Fatima H, Qureshi A, Kumar S, Hanan A, Hussain J, *et al.* Drawbacks of artificial intelligence and their potential solutions in the healthcare sector. Biomed Mater Devices 2023. p. 1-8. [doi: 10.1007/s44174-023-00063-2].
64. Yang G, Ye Q, Xia J. Unbox the black-box for the medical explainable

AI via multi-modal and multi-centre data fusion: A mini-review, two showcases and beyond. Inf Fusion 2022;77:29-52.
65. Naik N, Hameed BM, Shetty DK, Swain D, Shah M, Paul R, *et al.* Legal and ethical consideration in artificial intelligence in healthcare: Who takes responsibility? Front Surg 2022;9:862322.
66. Adeyoju A. Nigeria: The Role of Intellectual Property in Artificial Intelligence. AELEX. Mondaq; 2019. Available from: https://www.mondaq.com/nigeria/patent/794610/the-role-of-intellectual-property-in-artificial-intelligence. [Last accessed on 2023 Sep 15].
67. Da Bormida M. The big data world: Benefits, threats and ethical challenges. In: Ethical Issues in Covert, Security and Surveillance Research. Vol. 8. United Kingdom: Emerald Publishing Limited; 2021. p. 71-91.
68. Conroy D. Accelerating Drug Development to Keep Pace with Drug Discovery. Forbes; 2023. Available from: https://www.forbes.com/sites/forbestechcouncil/2023/03/10/accelerating-drug-development-to-keep-pace-with-drug-discovery/?sh=ff64215a5da9. [Last accessed on 2023 Sep 15].
69. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, *et al.* Precision medicine, AI, and the future of personalized health care. Clin Transl Sci 2021;14:86-93.
70. Schork NJ. Artificial intelligence and personalized medicine. Cancer Treat Res 2019;178:265-83.
71. Domnisch N. Unlocking the Potential of AI-Powered Personalized Medicine for Small and Medium-Sized Businesses. Forbes Technology Council; 2023. Available from: https://www.forbes.com/sites/forbestechcouncil/2023/07/05/unlocking-the-potential-of-ai-powered-personalized-medicine-for-small-and-medium-businesses/?sh=3e271d375f51. [Last accessed on 2023 Sep 15].
72. van der Schaar M. AI-Powered Personalised Medicine Could Revolutionise Healthcare (and No, We're not Putting ChatGPT in Charge). The Guardian; 2023. Available from: https://www.theguardian.com/commentisfree/2023/jun/26/ai-personalise-medicine-patient-lab-health-diagnosis-cambridge. [Last accessed on 2023 Sep 15].
73. Buvailo A. AI Drug Discovery: Unleashing the Potential of Big Data and Machine Learning. Biopharma Insight/White Papers and Industry Reports. Publisher; 2023. Available from: https://www.biopharmatrend.com/post/24-3-ways-big-data-and-machine-learning-revolutionize-drug-discovery/(Accession No. 28264). [Last accessed on 2023 Sep 15].
74. Allais F, Brogi S, Castro GR, Vidali VP. Advances in green synthesis for drug discovery. Front Chem 2023;11:1166887.
75. Johansson M, Douglas J. Striving for Sustainable Drug Discovery Using Green Chemistry; 2022. Available from: https://www.astrazeneca.com/what-science-can-do/topics/sustainability/Striving-for-sustainable-drug-discovery-using-Green-Chemistry.html. [Last accessed on 2023 Sep 15].
76. Wynendaele E, Furman C, Wielgomas B, Larsson P, Hak E, Block T, *et al.* Sustainability in drug discovery. Med Drug Discov 2021;12:100107.
77. Frąckiewicz M. The Benefits and Risks of AI in Drug Discovery and Development. TS2; 2023. Available from: https://ts2.space/en/the-benefits-and-risks-of-ai-in-drug-discovery-and-development/. [Last accessed on 2023 Sep 15].
78. UNESCO. Artificial Intelligence for Sustainable Development: Challenges and Opportunities for UNESCO's Science and Engineering Programmes (SC/PCB/WP/2019/AI); 2019. Available from: https://unesdoc.unesco.org/ark:/48223/pf0000368028. [Last accessed on 2023 Sep 15].
79. Thurzo A, Strunga M, Urban R, Surovková J, Afrashtehfar KI. Impact of artificial intelligence on dental education: A review and guide for curriculum update. Educ Sci 2023;13:150.